Psoriatic arthritis patients who stay on 1 anti-TNFi drug fare better

04/26/2013 | Family Practice News

Patients with psoriatic arthritis who switched to a second anti-tumor necrosis factor inhibitor drug had lower drug-survival rates at three years compared with those who remained on their first medication, researchers in Norway found. Switchers also showed much poorer responses in factors such as Disease Activity Score-28 remission and American College of Rheumatology-50 response than non-switchers. The findings were published in the journal Annals of the Rheumatic Diseases.

View Full Article in:

Family Practice News

Published in Brief:

SmartBrief Job Listings for Education

Job Title Company Location
Principal
Endeavor Charter Academy
Battle Creek, MI
Principal at Riverton Street Charter School
National Heritage Academies
Jamaica, NY
Chief Academic & Innovation Officer/ Assistant Superintendent
Kent School District
Kent, WA
School Improvement Officer
Kent School District
Kent, WA
Account Executive - Central Region
NWEA
Multiple Locations, SL_Multiple Locations